GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Equity-to-Asset

Vincerx Pharma (Vincerx Pharma) Equity-to-Asset : -0.06 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vincerx Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-0.62 Mil. Vincerx Pharma's Total Assets for the quarter that ended in Mar. 2024 was $11.08 Mil.

The historical rank and industry rank for Vincerx Pharma's Equity-to-Asset or its related term are showing as below:

VINC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.06   Med: 0.75   Max: 0.86
Current: -0.06

During the past 5 years, the highest Equity to Asset Ratio of Vincerx Pharma was 0.86. The lowest was -0.06. And the median was 0.75.

VINC's Equity-to-Asset is ranked worse than
85.44% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs VINC: -0.06

Vincerx Pharma Equity-to-Asset Historical Data

The historical data trend for Vincerx Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Equity-to-Asset Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
- 0.40 0.85 0.80 0.62

Vincerx Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.68 0.60 0.62 -0.06

Competitive Comparison of Vincerx Pharma's Equity-to-Asset

For the Biotechnology subindustry, Vincerx Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vincerx Pharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's Equity-to-Asset falls into.



Vincerx Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Vincerx Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=11.222/18.217
=

Vincerx Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=-0.622/11.083
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vincerx Pharma  (NAS:VINC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Vincerx Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vincerx Pharma (Vincerx Pharma) Business Description

Traded in Other Exchanges
N/A
Address
260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.
Executives
Alexander A. Seelenberger officer: Chief Financial Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi director, 10 percent owner, officer: Chief Operations Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy director, 10 percent owner, officer: President and CEO 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas officer: See Remarks 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe director 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang officer: Chief Business Officer 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang officer: Chief Technology Officer 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens director 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus officer: Chief Medical Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd 10 percent owner 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054

Vincerx Pharma (Vincerx Pharma) Headlines

From GuruFocus

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 06-16-2022